Specimen Repository for HIV Immunopathogenesis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03579381

Enrollment

Registered

2018-07-06

Start date

2017-07-31

Completion date

2019-01-25

Last updated

2021-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute HIV Infection, HIV-1-infection

Brief summary

Specimen Repository for HIV Immunopathogenesis Studies

Detailed description

The goal is to build a large specimen repository for collaborating scientists to run studies of immunity and HIV-1.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

1. HIV positive (acutely infected, viremic and elite controllers) 2. Signed Informed Consent Form 3. Age at least 18 years old 4. Immune controllers, two types: Elite suppressors (HIV-positive with any three consecutive plasma HIV-1 RNA PCR undetectable while off treatment) or viremic suppressors (HIV-positive with any three consecutive HIV-1 RNA PCR \<3000 while off treatment). 5. Acutely infected subjects: Persons identified to have a negative HIV antibody response (ELISA) but positive detection of HIV-1 in the blood (RT-PCR) or individuals who have evidence of a recent (past 30 days) HIV negative result along with a current HIV positive result.

Exclusion criteria

1. Uncontrolled bleeding diathesis. 2. Pregnant. 3. Inability to provide informed consent.

Design outcomes

Primary

Measure	Time frame	Description
HIV progression from acute infection to viral suppression	2 years	Outcomes will depend on scientists who use the samples for further study
HIV progression and control by elite and viremic suppressors	2 years	Outcomes will depend on scientists who use the samples for study

Countries

United States

Outcome results